Source:http://linkedlifedata.com/resource/pubmed/id/20981340
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2010-10-28
|
| pubmed:abstractText |
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:status |
PubMed-not-MEDLINE
|
| pubmed:issn |
2042-0064
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
2010
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
941419
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Sclerostin.
|
| pubmed:affiliation |
Cedars-Sinai, UCLA, OMC Clinical Research Center, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA.
|
| pubmed:publicationType |
Journal Article
|